+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Management of venous thromboembolism in cancer patients and the role of the new oral anticoagulants



Management of venous thromboembolism in cancer patients and the role of the new oral anticoagulants



Blood Reviews 28(1): 1-8



Patients with cancer are at high risk for venous thromboembolism (VTE). Most clinical guidelines agree that low-molecular-weight heparins (LMWHs) are the preferred anticoagulants for the prevention and treatment of VTE in cancer patients. However, LMWHs require daily injections, weight-adjustment of dose, and can be associated with heparin-induced thrombocytopenia; all of which are important considerations in managing cancer-associated VTE. Comparatively, the new oral anticoagulants offer a more attractive option because of their oral administration, fixed-dose, and lack of routine laboratory monitoring. The results of phase III trials support the efficacy and safety of the new oral anticoagulants in the management of VTE. However, generalizing these findings to cancer patients with VTE is difficult since very few cancer patients were included. In this comprehensive review, we provide an overview of the current treatment of VTE, explore anticoagulant thromboprophylaxis in ambulatory cancer patients, and summarize existing evidence on the efficacy and safety of the new oral anticoagulants for the management of VTE in both non-cancer and cancer populations.

(PDF emailed within 0-6 h: $19.90)

Accession: 054248141

Download citation: RISBibTeXText

PMID: 24360911

DOI: 10.1016/j.blre.2013.11.001


Related references

Management of venous thromboembolism in patients with advanced gastrointestinal cancers: what is the role of novel oral anticoagulants?. Thrombosis 2012: 758385-758385, 2012

The role of direct oral anticoagulants in the management of venous thromboembolism. American Journal of Managed Care 23(20 Suppl): S383-S390, 2018

The use of novel oral anticoagulants in cancer patients with venous thromboembolism. Seminars in Oncology 43(6): 655-665, 2017

Role of direct oral anticoagulants in the treatment of cancer-associated venous thromboembolism: guidance from the SSC of the ISTH. Journal of Thrombosis and Haemostasis, 2018

The role of direct oral anticoagulants in cancer-related venous thromboembolism: a perspective beyond the guidelines. Supportive Care in Cancer, 2017

Use of Direct Oral Anticoagulants for Treating Venous Thromboembolism in Patients With Cancer. Journal of the National Comprehensive Cancer Network 16(5s): 670-673, 2018

Pros and cons of new oral anticoagulants in the treatment of venous thromboembolism in patients with cancer. Internal and Emergency Medicine 10(6): 651-656, 2015

The use of direct oral anticoagulants in the treatment of acute venous thromboembolism in cancer patients. Expert Review of Hematology, 2018

Ischemic stroke in cancer patients treated with direct oral anticoagulants for venous thromboembolism. Thrombosis Research 154: 16-18, 2017

Meta-analysis of the efficacy and safety of new oral anticoagulants in patients with cancer-associated acute venous thromboembolism. Journal of Thrombosis and Haemostasis 12(7): 1116-1120, 2015

Real-life Use of Anticoagulants in Venous Thromboembolism With a Focus on Patients With Exclusion Criteria for Direct Oral Anticoagulants. Clinical Pharmacology and Therapeutics, 2017

Potential role of new anticoagulants for prevention and treatment of venous thromboembolism in cancer patients. Vascular Health and Risk Management 9: 207-228, 2013

Oral anticoagulants in the management of venous thromboembolism. Nature Reviews Cardiology 10(7): 397-409, 2013

Assessment of venous thromboembolism treatment in patients with cancer on low molecular weight heparin, warfarin, and the direct oral anticoagulants. Journal of Oncology Pharmacy Practice 1078155217730129-1078155217730129, 2017

PO-40 - Real-life use of non-vitamin k antagonist oral anticoagulants in patients with cancer associated venous thromboembolism: data from a prospective cohort. Thrombosis Research 140 Suppl 1(): S191-S191, 2016